USPTO serial 78359775
SEPPRO
Reviewed by CopyMark Law Group
Reg. 3007344Status 710
- Filing date
- Status date
- Registration date
- Oct 18, 2005
- Examiner
- BENMAMAN, ALICE
- Law office
- GENERIC WEB UPDATE
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SEPPRO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
DARMSTADT, DE
San Diego, CA, US
San Diego, CA, US
ST. LOUIS, MO, US
SIGMA-ALDRICH BIOTECHNOLOGY L.P.
ST. LOUIS, MO, US
San Diego, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William C. Wright
William C. Wright Epstein Drangel LLP60 East 42nd Street, Suite 2520New York, NY 10165UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for fractionating target proteins from complex biological fluids, such as plasma, serum, CSF, urine or other tissue or cellular sources, and the subsequent chemical analysis of compounds physiologically associated with abundant proteins including proteins, peptides, fatty acids, hormones, glycosylation states, phosphorylation states, etc; Reagents for diagnosis of diseases associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Immunoaffinity reagents for developing chemical markers that indicate the presence of disease states associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Reagents for determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions related to albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3 and associated compounds in humans and animals; Reagents for determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3, all for research use | SECTION 8 - CANCELLED | Jan 28, 2004 |
| 042 | Product development, medical and laboratory research in the field of proteomics, namely the science, system, components, organization, function, and biomedical applications of separation of abundant proteins, especially, in the area of proteomics sample processing that permits highly selective separation of abundant proteins, such as albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; development of chemical markers that indicate the presence of disease states; determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions in humans and animals; determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets; developing methodologies relating to the previous services such as developing bioanalytical methods to increase sensitivity, specificity and throughput of identifying and characterizing biological substances such as protein, peptides, hormones, lipids, used as biomarkers for a diagnosis or as drug targets | SECTION 8 - CANCELLED | Jan 28, 2004 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MERCK KGAA
- Other trademarks owned by GenWay Biotech, Inc.
- Other trademarks owned by GenWay Biotech, Inc.
- Other trademarks owned by SIGMA-ALDRICH CO., LLC
- Other trademarks owned by SIGMA-ALDRICH BIOTECHNOLOGY L.P.
- Other trademarks owned by GenWay Biotech, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 042
- Similar marks named SEPPRO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 1, 2026 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Oct 18, 2024 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| May 20, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 20, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 20, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 20, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 20, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 20, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 28, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 22, 2015 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Sep 22, 2015 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Sep 22, 2015 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Sep 22, 2015 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 24, 2015 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Aug 24, 2015 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 21, 2012 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Apr 21, 2012 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Apr 21, 2012 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 9, 2012 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Oct 4, 2011 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 4, 2011 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 14, 2011 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Mar 11, 2009 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 18, 2005 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 26, 2005 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 6, 2005 | NPUB | NOTICE OF PUBLICATION | — |
| May 26, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 23, 2005 | ALIE | ASSIGNED TO LIE | — |
| May 13, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 13, 2005 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 13, 2005 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 11, 2005 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 22, 2005 | CWBP | WITHDRAWN BEFORE PUBLICATION | — |
| Jan 27, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 25, 2005 | ALIE | ASSIGNED TO LIE | — |
| Jan 11, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 10, 2005 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 10, 2005 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 8, 2004 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Dec 1, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 1, 2004 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 26, 2004 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 20, 2004 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 9, 2004 | NWAP | NEW APPLICATION ENTERED | — |